Why FDA approval for vepdegestrant is a major shift in cancer therapy
Vepdegestrant (brand name: Veppanu), developed by Arvinas and Pfizer, received FDA approval on 1 May 2026 — making it the first PROTAC (Proteolysis-Targeting Chimera) drug to receive regulatory approval for any disease.
The drug is approved for adults with ESR1-mutated, oestrogen receptor-positive (ER+), HER2-negative advanced or metastatic breast cancer that has progressed after at least one endocrine therapy.
Approval was based on the Phase 3 VERITAC-2 clinical trial, which showed a 43% reduction in disease progression risk compared to fulvestrant, with median progression-free survival of 5 months (vs. 2.1 months for fulvestrant) in the ESR1-mutant subgroup.
The approval is considered a paradigm shift in oncology — validating over two decades of research into targeted protein degradation as a drug modality distinct from conventional receptor blockade.
PROTAC Technology: Mechanism and Significance
PROTACs (Proteolysis-Targeting Chimeras) are bifunctional small molecules that simultaneously bind to a target protein of interest (POI) and to an E3 ubiquitin ligase enzyme. This physical proximity causes the E3 ligase to tag the target protein with ubiquitin chains, which marks it for destruction by the cell's own intracellular waste-disposal system — the 26S proteasome. Unlike conventional drugs that block a protein's active site (inhibition), PROTACs cause complete removal of the protein from the cell. This is conceptually important because the PROTAC molecule is catalytic: after the target protein is degraded, the PROTAC is released and can engage another molecule of the target — making it effective at far lower concentrations than a stoichiometric inhibitor.
Key Details
- PROTACs first described by Kathleen Sakamoto, Craig Crews, and Raymond Deshaies in 2001 (Yale/Caltech).
- Arvinas Inc. founded in 2013 by Craig Crews to commercialise PROTAC technology.
- Mechanism: PROTAC → binds POI + E3 ubiquitin ligase → ubiquitination of POI → proteasomal degradation.
- Catalytic mode: Unlike inhibitors, one PROTAC molecule can degrade multiple copies of the target protein.
- Key E3 ligases exploited in PROTAC design: CRBN (cereblon), VHL (Von Hippel–Lindau), MDM2, IAP.
- Vepdegestrant binds the oestrogen receptor (ER) and recruits CRBN (cereblon) E3 ligase.
Vepdegestrant's approval validates the PROTAC concept that has been in laboratory development since 2001 — providing the first proof in humans that targeted protein degradation can be a clinically effective and safe drug modality.
Ubiquitin-Proteasome System (UPS): The Cell's Protein Quality Control
The ubiquitin-proteasome system (UPS) is the cell's primary mechanism for regulated protein degradation. Ubiquitin is a small 76-amino acid protein that acts as a molecular "tag." Enzymes called E1 (ubiquitin-activating), E2 (ubiquitin-conjugating), and E3 (ubiquitin ligase) work in sequence to attach ubiquitin chains to target proteins. Proteins tagged with polyubiquitin chains are recognised and degraded by the 26S proteasome — a large barrel-shaped protein complex. The UPS is responsible for degrading misfolded, damaged, or no-longer-needed proteins, regulating cell-cycle progression, transcription factor activity, and immune signalling. PROTACs hijack this endogenous system to degrade disease-causing proteins on demand.
Key Details
- Ubiquitin: 76-amino acid protein; encoded by a small gene family; highly conserved across eukaryotes.
- E1–E2–E3 cascade: E1 activates ubiquitin, E2 conjugates it, E3 ligase confers target specificity.
- There are approximately 600 E3 ubiquitin ligases in the human genome — offering wide target diversity for PROTAC design.
- 26S proteasome: Cylindrical protease complex that degrades ubiquitin-tagged proteins into short peptides.
- UPS dysregulation is implicated in cancer, neurodegenerative diseases (Parkinson's, Alzheimer's), and autoimmune disorders.
- Bortezomib (approved 2003) — an earlier drug that works by inhibiting the proteasome — was a precursor therapeutic exploitation of this pathway.
Vepdegestrant is the first drug to exploit UPS not by inhibiting the proteasome globally (as bortezomib does) but by directing the system to degrade a specific disease-causing protein — a far more targeted approach.
"Undruggable" Proteins and the Therapeutic Frontier
Approximately 80% of human proteins implicated in disease are considered "undruggable" by conventional small-molecule inhibitors. A protein is undruggable when it lacks a deep binding pocket suitable for a small molecule to occupy and block function — transcription factors, scaffold proteins, and many protein-protein interaction surfaces fall in this category. Conventional drug design requires a target protein to have a "druggable" binding site. PROTAC technology bypasses this requirement: because PROTACs degrade rather than block, they only need to bind transiently to the target, not occupy its functional site. This opens the therapeutic frontier to a large class of proteins — including many oncogenes and transcription factors — that have been inaccessible to classical drug design.
Key Details
- Approximately 80% of disease-implicated proteins are estimated to be "undruggable" by classical inhibitors.
- ESR1 mutation in breast cancer alters the oestrogen receptor in ways that reduce inhibitor effectiveness — making degradation more effective than blockade.
- Other potential PROTAC targets in development: KRAS (pancreatic/lung cancer), AR (prostate cancer), tau aggregates (Alzheimer's).
- PROTAC research pipeline as of 2026 has several candidates in Phase 1 and Phase 2 clinical trials.
Vepdegestrant targets ESR1-mutated oestrogen receptor — a protein that acquires resistance-conferring mutations that reduce the effectiveness of conventional oestrogen receptor inhibitors. Degrading the receptor entirely is more effective in this mutation context than blocking it.
Drug Approval Process: FDA Pathways and Clinical Significance
The U.S. Food and Drug Administration (FDA) is the primary regulatory authority for therapeutic drug approval in the United States. Its approval decisions carry global weight as a benchmark for drug safety and efficacy — many countries rely on FDA approvals in their own review processes. FDA approval for oncology drugs typically follows a New Drug Application (NDA) or Biologics License Application (BLA) based on Phase 1, 2, and 3 clinical trial data. The FDA can grant Breakthrough Therapy Designation, Fast Track, Priority Review, or Accelerated Approval for drugs targeting serious conditions with unmet medical need.
Key Details
- FDA approval date for vepdegestrant: 1 May 2026.
- Based on: Phase 3 VERITAC-2 trial — 43% reduction in disease progression risk vs. fulvestrant (standard of care).
- Approved indication: Second-line treatment for ESR1-mutated, ER+/HER2− metastatic breast cancer.
- Historical significance: First-in-class approval for any PROTAC drug globally.
- ER+ HER2− is the most common subtype of metastatic breast cancer globally.
The FDA approval establishes vepdegestrant as a new standard-of-care option for a defined subgroup of metastatic breast cancer patients and simultaneously validates PROTAC as a drug class — triggering accelerated development of PROTACs for other indications.
- Vepdegestrant brand name: Veppanu; developers: Arvinas and Pfizer.
- FDA approval: 1 May 2026 — first-ever PROTAC to receive regulatory approval.
- Indication: ESR1-mutated, ER-positive, HER2-negative advanced/metastatic breast cancer; second-line after endocrine therapy failure.
- VERITAC-2 trial result: 43% reduction in disease progression risk vs. fulvestrant; median PFS 5 months vs. 2.1 months in ESR1-mutant subgroup.
- PROTACs first described: 2001 (Sakamoto, Crews, Deshaies).
- Arvinas Inc. founded: 2013 by Craig Crews.
- Mechanism: Bifunctional molecule binding target protein + cereblon (CRBN) E3 ligase → ubiquitination → proteasomal degradation.
- Number of E3 ubiquitin ligases in the human genome: ~600.
- Approximately 80% of disease-implicated proteins are estimated undruggable by conventional inhibitors.